$TLTFF .18-.435 5 YEAR RANGE. PPS soon to deliver Rangebound breakout!
The science and results are just too good.
CV19 had the PPS declined.
The company's exellent results from the PH2 bladder cancer study are about to get even better due to optimized protocol.